When National Security Becomes a Deal Term: What the Korea Zinc Battle and Roche-PathAI Tell Us About 2026 M&A
In the first week of May 2026, two stories landed on opposite sides of the Pacific — and they told the same story. In Seoul, The Korea Herald and The Investor reported that national security reviews are no longer a predictable procedural step in Korean cross-border M&A. They have become a strategic weapon. Lawmakers from both ruling and opposition parties are now pushing legislation that would extend security screening to minority stake acquisitions and indirect investments — not just controlling interests. The Korea Zinc vs. MBK battle in 2024 was the opening act: a domestic private equity firm with significant foreign investor exposure was subjected to national security arguments by the target company's management as a defense mechanism. In Boston, Roche announced on May 7 that it has entered into a definitive merger agreement to acquire PathAI — an AI-powered digital pathology company — for $750 million upfront, with milestone payments of up to $300 million additional, for a...